Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.

Masashi KatoAkihiro HirakawaHiroyuki SatoRyoichi HanazawaYushi NaitoKosuke TochigiTomoyasu SanoShohei IshidaYasuhito FunahashiTakashi FujitaYoshihisa MatsukawaRyohei HattoriToyonori Tsuzuki

Published in: International journal of clinical oncology (2021)

Our findings suggest that GG2 (GP4 ≤ 10%) patients could be indicated for AS, similar to GG1 patients, given the risk of IDC-P tumors.

Keyphrases

end stage renal disease
newly diagnosed
prostate cancer
prognostic factors
peritoneal dialysis
risk assessment
patient reported outcomes